Titre:
  • Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.
Auteur:Azambuja, Evandro; Zardavas, Dimitros; Lemort, Marc; Rossari, José; Moulin, C; Buttice, A; D'Hondt, Veronique; Lebrun, Fabienne; Lalami, Yassine; Cardoso, Fatima; Sotiriou, Christos; Gil, Thierry; Devriendt, Daniel; Paesmans, M.; Piccart-Gebhart, Martine; Awada, Ahmad
Informations sur la publication:Annals of oncology, 24, 12, page (2985-2989)
Statut de publication:Publié, 2013-12
Sujet CREF:Cancérologie
Médecine pathologie humaine
MeSH keywords:Adult
Aged
Antineoplastic Combined Chemotherapy Protocols -- pharmacology -- therapeutic use
Brain Neoplasms -- drug therapy -- metabolism -- mortality -- secondary
Breast Neoplasms -- drug therapy -- metabolism -- mortality -- pathology
Dacarbazine -- administration & dosage -- analogs & derivatives
Disease-Free Survival
Female
Humans
Maximum Tolerated Dose
Middle Aged
Quinazolines -- administration & dosage
Receptor, ErbB-2 -- metabolism
Treatment Outcome
Note générale:Journal Article
Research Support, Non-U.S. Gov't
SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0923-7534
info:doi/10.1093/annonc/mdt359
info:pii/mdt359
info:scp/84888804829
info:pmid/24013582